KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Pacific Biosciences Of California (PACB) over the last 17 years, with Q3 2025 value amounting to $11.0 million.

  • Pacific Biosciences Of California's Share-based Compensation fell 3984.34% to $11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.1 million, marking a year-over-year decrease of 3279.09%. This contributed to the annual value of $71.0 million for FY2024, which is 150.03% down from last year.
  • Pacific Biosciences Of California's Share-based Compensation amounted to $11.0 million in Q3 2025, which was down 3984.34% from $11.9 million recorded in Q2 2025.
  • Over the past 5 years, Pacific Biosciences Of California's Share-based Compensation peaked at $35.8 million during Q3 2021, and registered a low of $9.2 million during Q1 2025.
  • Moreover, its 5-year median value for Share-based Compensation was $18.0 million (2023), whereas its average is $17.6 million.
  • Per our database at Business Quant, Pacific Biosciences Of California's Share-based Compensation skyrocketed by 61754.81% in 2021 and then tumbled by 5287.58% in 2025.
  • Over the past 5 years, Pacific Biosciences Of California's Share-based Compensation (Quarter) stood at $18.9 million in 2021, then dropped by 5.19% to $18.0 million in 2022, then decreased by 7.64% to $16.6 million in 2023, then dropped by 3.32% to $16.0 million in 2024, then crashed by 31.49% to $11.0 million in 2025.
  • Its Share-based Compensation stands at $11.0 million for Q3 2025, versus $11.9 million for Q2 2025 and $9.2 million for Q1 2025.